Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.3.1 or 3.3.3, then CombinatoRx shall notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within fifteen (15) days after such written notice to discuss in good faith for a period of not more than fifteen (15) days CombinatoRx's concerns and Fovea's development activities with respect to the Collaboration Combination.
Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Flexion is in breach of its obligations under Section 5.3 with respect to a Major Market, then AstraZeneca shall so notify Flexion, specifying the basis for its belief, and the Parties shall meet […***…] after such notice to discuss in good faith AstraZeneca’s concerns and Flexion’s Development and commercialisation plans with respect to the Licensed Product(s) to attempt to eliminate AstraZeneca’s concerns.
Notification and Meeting. If either party learns that a third party (the "Infringer") is:
Notification and Meeting. If at any time NovaDel has a reasonable basis to believe that Licensee is in breach of its obligations under Article 3.8 with respect to a country in the Territory, NovaDel shall notify Licensee thereof, specifying the basis for its belief, and the Parties shall meet within ten (10) days after such notice to discuss in good faith NovaDel's concerns and Licensee's activities with respect to the Licensed Products in such country.
Notification and Meeting. If at any time a Party has a reasonable basis to believe that the other Party (the “Pursuing Party”) is in material breach of a material obligation under Section 4.12.1 with respect to a Collaboration Antigen or Discontinued Antigen, as applicable, then the non-Pursuing Party shall so notify the Pursuing Party, specifying the basis for its belief, and the Parties shall meet within [Confidential treatment requested] after such notice to discuss in good faith the non-Pursuing Party’s concerns and the Pursuing Party’s development and commercialization plans with respect to such Antigen.
Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Neoprobe is in breach of its obligations under Section 5.2 with respect to a Major Market, then AstraZeneca shall so notify Neoprobe, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such notice to discuss in good faith AstraZeneca’s concerns and Neoprobe’s development and commercialisation plans with respect to the Licensed Product. Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.
Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Angiotech is in breach of its material obligations under Section 7.2, then CombinatoRx shall so notify Angiotech in writing, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such written notice to discuss in good faith for a period of not more than twenty-one (21) days CombinatoRx's concerns and Angiotech's development and commercialization plans with respect to the Licensed Compound and Licensed Product.
Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Neoprobe is in breach of its obligations under Section 5.2 with respect to a Major Market, then AstraZeneca shall so notify Neoprobe, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such notice to discuss in good faith AstraZeneca’s concerns and Neoprobe’s development and commercialisation plans with respect to the Licensed Product.
Notification and Meeting. If AstraZeneca is in material breach of its obligations under Section 6.1, then Palatin shall so notify AstraZeneca and the Parties shall meet within *** after such notice to discuss in good faith AstraZeneca’s development and commercialisation plans with respect to the Agreement Compound and Licensed Product.
Notification and Meeting. If at any time Avanir has a reasonable basis to believe that AstraZeneca is in breach of its material obligations under Section 8.1, then Avanir shall so notify AstraZeneca, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such notice to discuss in good faith Avanir's concerns and AstraZeneca's development and commercialisation plans with respect to the Licensed Compound and Licensed Product.
